Literature DB >> 2478616

Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice.

C Barra1, B Pérarnau, P Gerlinger, M Lemeur, A Gillet, P Gibier, F A Lemonnier.   

Abstract

The cytolytic responses of either normal (non transgenic), HLA-B7 (single transgenic) or HLA-B7 x human beta 2 microglobulin (double transgenic) DBA/2 mice induced by transfected HLA-Cw3 P815 (H-2d) mouse mastocytoma cells were compared, to evaluate whether the expression of an HLA class I molecule in responder mice would favor the emergence of HLA-specific, H-2-unrestricted CTL. Only 8 of 300 HLA-Cw3-specific CTL clones tested could selectively lyse HLA-Cw3-transfected cells in an H-2-unrestricted manner, all having been isolated after hyperimmunization of double transgenic mice. These clones also lysed HLA-Cw3+ human cells. Unexpectedly, the lysis of the human but not that of the murine HLA-Cw3 cells was inhibited by Ly-2,3-specific mAb. Despite significant expression of HLA-B7 class I molecules on transgenic lymphoid cells, including thymic cells, limiting dilution analysis and comparative study of TCR-alpha and -beta gene rearrangements of the eight isolated clones (which suggested that they all derived from the same CTL precursor) indicated that the frequency of HLA-Cw3-specific H-2 unrestricted cytotoxic T lymphocytes remained low (even in HLA-B7 x human beta 2-microglobulin double transgenic mice). This suggests that coexpression of HLA class I H and L chain in transgenic mice is not the only requirement for significant positive selection of HLA class I-restricted cytotoxic mouse T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478616

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Xenogeneic proliferation and lymphokine production are dependent on CD4+ helper T cells and self antigen-presenting cells in the mouse.

Authors:  R D Moses; R N Pierson; H J Winn; H Auchincloss
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

2.  Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.

Authors:  S Peng; C Trimble; L He; Y-C Tsai; C-T Lin; D A K Boyd; D Pardoll; C-F Hung; T-C Wu
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

3.  HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.

Authors:  Rachid Boucherma; Hédia Kridane-Miledi; Romain Bouziat; Michael Rasmussen; Tanja Gatard; Francina Langa-Vives; Brigitte Lemercier; Annick Lim; Marion Bérard; Lbachir Benmohamed; Søren Buus; Ronald Rooke; François A Lemonnier
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

4.  Recognition of HLA-B27 by mouse cytotoxic T-cell clones: a transgenic mouse model.

Authors:  M Reboul; B Frangoulis; A Rocca; L Degos; M Pla
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

5.  Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development.

Authors:  Jinliang Li; Tumul Srivastava; Ravindra Rawal; Edwin Manuel; Donna Isbell; Walter Tsark; Corinna La Rosa; Zhongde Wang; Zhongqi Li; Peter A Barry; Katharine D Hagen; Jeffrey Longmate; Don J Diamond
Journal:  Virology       Date:  2009-02-27       Impact factor: 3.616

6.  HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice.

Authors:  S Pascolo; N Bervas; J M Ure; A G Smith; F A Lemonnier; B Pérarnau
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

7.  H-2-restricted cytolytic T lymphocytes specific for HLA display T cell receptors of limited diversity.

Authors:  J L Casanova; J C Cerottini; M Matthes; A Necker; H Gournier; C Barra; C Widmann; H R MacDonald; F Lemonnier; B Malissen; J L Maryanski
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.